RDY
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 19.06, PEG 3.77, Graham Number $3.61
- P/E is lower than the broad healthcare sector average
- Price is ~3.8x the Intrinsic Value
- Price/Book of 17.01 is excessively high
- PEG ratio of 3.77 is poor
Ref Growth rates
- Modest revenue growth (4.4%)
- Earnings growth is negative (-14.3%)
- Forward P/E expansion suggests lower future earnings
Ref Historical trends
- Long history of beating earnings estimates
- Positive 3Y price change (+15.4%)
- Recent 1Y performance is flat (-0.2%)
Ref Piotroski F-Score 4/9, Debt/Equity 0.18
- Very low debt levels
- Strong current and quick ratios
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Ref Yield 0.67%, Payout 11.82%
- Low payout ratio (11.82%) ensures sustainability
- Very low dividend yield (0.67%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RDY and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Limited
Primary
|
+2.5% | +15.4% | -0.2% | +3.2% | +1.9% | +0.4% |
|
ELAN
Elanco Animal Health Incorporated
Peer
|
-26.6% | +143.8% | +140.5% | +3.2% | -10.8% | -3.9% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+116.3% | +96.7% | +49.7% | +1.9% | -5.3% | -3.9% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
MDGL
Madrigal Pharmaceuticals, Inc.
Peer
|
+281.0% | +67.6% | +52.2% | +23.0% | +2.6% | -2.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Limited
|
BEARISH | $11.45B | 19.06 | 16.1% | 16.4% | $13.72 | |
|
ELAN
Elanco Animal Health Incorporated
|
NEUTRAL | $11.36B | - | -3.7% | -4.9% | $22.75 | Compare |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.1B | 32.47 | 16.9% | 6.8% | $189.94 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
NEUTRAL | $11.9B | - | -42.5% | -30.1% | $518.58 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning RDY from our newsroom.